We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Brain Plaque Diagnostic PET Imaging Agent Receives Approval

By MedImaging International staff writers
Posted on 19 Apr 2012
In 2011, Eli Lilly (Indianapolis, IN, USA) was unsuccessful in gaining the US Food and Drug Administration’s (FDA) approval to use its radioactive diagnostic agent Amyvid (Florbetapir F-18 injection) for diagnosis of Alzheimer’s disease (AD) in patients. In the second attempt, it has finally obtained a positive regulatory approval, but for a more general indication.

The company announced in April 2012 that the FDA approved the agent for use with positron emission tomography (PET) imaging scans to identify beta-amyloid plaque in a living patient’s brain. Targeted patients can be suspected of having Alzheimer’s or other causes of cognitive decline. Lilly subsidiary Avid Radiopharmaceuticals (Philadelphia, PA, USA), the developer of the diagnostic agent, cautioned, however, that its new product will aid in AD diagnoses, but is not a definitive tool because the plaque can also be involved in other conditions. Physicians typically do not know for sure if a patient has AD until after the patient dies and they perform an autopsy.

“It’s estimated that one in five patients clinically diagnosed with probably Alzheimer’s disease during life do not end up having Alzheimer’s disease pathology upon autopsy,” Avid president and CEO Daniel Skovronsky said in a statement. “The approval …offers physicians a tool that, in conjunction with other diagnostic evaluations, can provide information to help physicians evaluate their patients.”

The hope is that the diagnostic will help identify the amyloid presence earlier, and subsequently determine more rapidly if a patient likely has AD. Then, physicians could begin treatments earlier in the deteriorating process.

The contrast agent binds to the beta amyloid, and physicians can then see it light up during a PET scan. The FDA rejected the initial approval application over concerns that physicians could have trouble interpreting the plaque scans. Since then, the company has developed a more detailed training program.

Related Links:

Eli Lilly
Avid Radiopharmaceuticals


Wall Fixtures
MRI SERIES
New
Breast Localization System
MAMMOREP LOOP
Ultrasound-Guided Biopsy & Visualization Tools
Endoscopic Ultrasound (EUS) Guided Devices
Silver Member
X-Ray QA Meter
T3 AD Pro

Channels

Ultrasound

view channel
Image: The new implantable device for chronic pain management is small and flexible (Photo courtesy of The Zhou Lab at USC)

Wireless Chronic Pain Management Device to Reduce Need for Painkillers and Surgery

Chronic pain affects millions of people globally, often leading to long-term disability and dependence on opioid medications, which carry significant risks of side effects and addiction.... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.